AT-121

• CAT Number: I015057
• CAS Number: 2099681-31-7
• Molecular Formula: C₂₄H₃₈N₄O₃S
• Molecular Weight: 462.65
• Purity: ≥95%
• Target: Neuronal Signaling
• IUPAC Name: 3-oxo-1'-(4-propan-2-ylcyclohexyl)-2-[2-(sulfamoylamino)ethyl]spiro[1H-isoquinoline-4,4'-piperidine]
• InChI: InChI=1S/C24H38N4O3S/c1-18(2)19-7-9-21(10-8-19)27-14-11-24(12-15-27)22-6-4-3-5-20(22)17-28(23(24)29)16-13-26-32(25,30)31/h3-6,18-19,21,26H,7-17H2,1-2H3,(H2,25,30,31)
• InChIKey: LIZMNXKYQXVRSS-UHFFFAOYSA-N
• SMILES: CC(C)C1CCC(CC1)N2CCC3(CC2)C4=CC=CC=C4CN(C3=O)CCNS(=O)(=O)N

AT-121（Cat No.:I015057）is an investigational drug developed by Atlantic Pharmaceuticals, designed as a dual-acting opioid receptor modulator. It targets both the mu-opioid receptor and the nociceptin/orphanin FQ peptide (NOP) receptor, aiming to provide pain relief while minimizing the risk of opioid dependence and abuse. AT-121 has shown promise in preclinical and early clinical trials for its potential to offer effective pain management without the addictive side effects of traditional opioids. Further clinical studies are required to confirm its safety, efficacy, and long-term benefits in treating chronic pain conditions.